Posts

Argenx's Vyvgart and Vyvgart Hytrulo Receive FDA Label Expansion for All Adult gMG Patients

on

Argenx's Vyvgart Shows Positive Phase 3 Results in Seronegative Myasthenia Gravis

on

Argenx Prepares FDA Filing to Expand Vyvgart Use in Myasthenia Gravis After Late-Stage Trial Win

on

AstraZeneca's Self-Administered Myasthenia Gravis Drug Gefurulimab Clears Phase 3 Trial

on

Vor Bio's $4B+ Revival Deal for RemeGen's Autoimmune Drug Triggers Divergent Stock Moves

on

Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis

on

FDA Approves Johnson & Johnson's Imaavy: A New Treatment Option for Generalized Myasthenia Gravis

on

Descartes-08: Sustained Efficacy in Myasthenia Gravis as Cartesian Prepares for Phase III Trial

on

Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravis

on

Immunovant Shifts Focus to Next-Gen Drug Despite Positive Phase 3 Results for Batoclimab in Myasthenia Gravis

on

New Uplizna data drop in myasthenia gravis, while clock ticks on IgG4 decision

on